CLL1-targeted chimeric antigen receptors and uses thereof
CLL1-targeted chimeric antigen receptors address the lack of effective immunotherapy for AML by specifically targeting and killing CLL1-positive tumor cells, enhancing immune cell functions and cytokine secretion.
Patent Information
- Application Number
- JP2022529577
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2020-12-11
- Filing Date
- 2020-12-22
- Publication Date
- 2024-12-09
- Estimated Expiration
- 2040-12-22
AI Technical Summary
Current immunotherapy targeting CLL1 for acute myeloid leukemia (AML) is rare, and there is a need for effective therapies that can specifically target CLL1-positive tumor cells.
Development of CLL1-targeted chimeric antigen receptors (CARs) using anti-CLL1 antibodies as antigen-binding domains, combined with hinge, transmembrane, and signaling domains, specifically binding to CLL1-positive tumor cells and enhancing immune cell killing functions.
The CLL1-targeted CARs effectively target and kill CLL1-positive tumor cells, secreting cytokine IFN-γ, demonstrating a significant therapeutic potential for AML.
Smart Images

Figure 0007595961000004 
Figure 0007595961000005 
Figure 0007595961000006
Abstract
Description
[Technical field]
[0001] The present application relates to the field of biomedicine and to CLL1-targeting chimeric antigen receptors and uses thereof. [Background technology]
[0002] C-type lectin-like molecule 1 (CLL1), also known as C-type lectin domain family 12 member A (CLEC12A), is a type II transmembrane protein. Research has shown that CLL1 is restrictedly expressed in hematopoietic cells, mainly including cells derived from myeloid lineage in peripheral blood and bone marrow, including mononuclear cells, dendritic cells, granulocytes and most acute myeloid leukemia (AML) cells. It has been found that CLL1 is abundantly expressed in myeloid cells in peripheral blood and bone marrow, but not expressed in cells derived from myeloid lineage in peripheral tissues, for example, CLL1 is not found in tissue macrophages and tissue dendritic cells. Research has further found that CLL1 is expressed in AML stem cells (CD34+ / CD38-) and a small portion of hematopoietic progenitor cells (CD34+ / CD38+, or CD34+ / CD33+), but not in normal hematopoietic stem cells (CD34+ / CD38-, or CD34+ / CD33-).
[0003] Due to this unique expression mode, CLL1 is expected to be a potential target point for diagnosing and treating AML, but currently there are few reports of immunotherapy targeting CLL1. Summary of the Invention [Problem to be solved by the invention]
[0004] The present application provides a CLL1-targeting chimeric antigen receptor and its use, wherein the CLL1-targeting chimeric antigen receptor employs an anti-CLL1 antibody having binding ability to CLL1 as an antigen-binding domain, and can not only bind to purified or free CLL1 protein, but also to CLL1 protein on the cell surface, and immune cells expressing the CLL1-targeting chimeric antigen receptor have important application prospects in the field of tumor treatment. [Means for solving the problem]
[0005] In aspect 1, the present application provides a method for producing a method for manufacturing a semiconductor device comprising: comprising an antigen-binding domain, a hinge region, a transmembrane domain, and a signal transduction domain; the antigen binding domain is an anti-CLL1 antibody; A CLL1-targeting chimeric antigen receptor is provided.
[0006] In the present application, an anti-CLL1 antibody having binding ability to CLL1 is employed as the antigen-binding domain of a chimeric antigen receptor, which can specifically bind to CLL1-positive tumor cells to achieve specific targeting effect on CLL1-positive tumors.
[0007] In some specific embodiments, the antigen binding domain comprises the amino acid sequences set forth in SEQ ID NO:1 and SEQ ID NO:2, wherein SEQ ID NO:1 and SEQ ID NO:2 are linked via a linking peptide to form the anti-CLL1 antibody 19C1, wherein: SEQ ID NO: 1: QVQLQQSGAELMKPGASVKISKATGYTFSSYWIEWVKQRPGHGLEWIGEIFPGSGSIKYNEKFKGKATFTADTSSNTA YMQLSSLTSEDSAVHYCARGGTYNDYSLFDYWGQGTTLTVSS. SEQ ID NO: 2: QIVLTQSPAIMSASPGEKVTMTCSASSSVSYMYWYQQKPGSSPRLLIFDTSNLASGVPVRFSGSGSGTSYSLTISRMEAEDAATYYCQQWSSYPLTFGAGTKLELK.
[0008] In some specific embodiments, the antigen binding domain comprises the amino acid sequences set forth in SEQ ID NO:3 and SEQ ID NO:4, wherein SEQ ID NO:3 and SEQ ID NO:4 are linked via a linking peptide to form the anti-CLL1 antibody 23D7, wherein: SEQ ID NO: 3: QVQLQQPGSDLVRPGASVKLSCKASGYTFTRYWMHWVKQRPGHGLEWIGYIYPGSGTSNYDEKFKSKATLTVDTSSSTAYMQLSSLTSEDSAVYYCTREARYTMDYWGQGTSVTVSS. SEQ ID NO: 4: QIVLTQSPAIMSASPGEKVTMTCSASSSVSYIYWYQQKPGSSPGLLIYDTSNLASGVPVRFSGSGSGTSYSLTISRMEAEDAATYYCQQWSSFPPTFGAGTKLELK.
[0009] In some specific embodiments, the antigen binding domain comprises the amino acid sequences set forth in SEQ ID NO:5 and SEQ ID NO:6, wherein SEQ ID NO:5 and SEQ ID NO:6 are linked via a linking peptide to form the anti-CLL1 antibody 27H4, wherein: SEQ ID NO: 5: EVQLQQSGPELVKPGASVKISKASGYSFTGYHMHWVKQSHVKSLEWIGRINPYNGAASHNQKFKDKATLTVDKSSSTAYMELHSLTSEDSAVYYCARGWDYDGGYYAMDYWGQGTSVTVSS. SEQ ID NO: 6: DIVMSQSPSSLAVSVGEKVTMSCKSSQSLLYSDNQKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVKAEDLAVYYCQQYYTYPYTFGGGTKLEIK.
[0010] In some specific embodiments, the antigen binding domain comprises an amino acid sequence set forth in SEQ ID NO:7 and an amino acid sequence set forth in one of SEQ ID NOs:8-10, wherein SEQ ID NO:7 and SEQ ID NO:8 are linked via a linking peptide to form anti-CLL1 antibody H27H4L1, SEQ ID NO:7 and SEQ ID NO:9 are linked via a linking peptide to form anti-CLL1 antibody H27H4L2, or SEQ ID NO:7 and SEQ ID NO:10 are linked via a linking peptide to form anti-CLL1 antibody H27H4L3, SEQ ID NO: 7: EVQLVQSGAEVKKPGASVKVSCKASGYTFTGYHMHWVRQAPGQRLEWMGRINPYNGAASHNQKFKDRVTITRDTSASTAYMELSSLRSEDTAVYYCARGWDYDGGYYAMDYWGQGTLVTVSS. SEQ ID NO: 8: DIQMTQSPSSLSASVGDRVTITCKSSQSLLYSDNQKNYLAWYQQKPGKAPKLLIYWASTRESGVPSRFSGSGSGTDFTL TISSLQPEDFATYYCQQYYTYPYTFGQGTKLEIK. SEQ ID NO: 9: DIVMTQSPLSLPVTPGEPASISCKSSQSLLYSDNQKNYLAWYLQKPGQSPQLLIYWASTRESGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCQQYYTYPYTFGQGTKLEIK. SEQ ID NO: 10: DIVMTQSPDSLAVSLGERATINCKSSQSLLYSDNQKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYTYPYTFGQGTKLEIK.
[0011] In some specific embodiments, the antigen binding domain comprises the amino acid sequences set forth in SEQ ID NO:11 and SEQ ID NO:12, where SEQ ID NO:11 and SEQ ID NO:12 are linked via a linking peptide to form the anti-CLL1 antibody 1075.7, SEQ ID NO: 11: DIQLQESGPGLVKPSQSLSLTCSVTGYSITSAYYWNWIRQFPGNKLEWMGYISYDGRNNYNPSLKNRISITRDTSKNQFFLKLNSVTTEDTATYYCAKEGDYDVGNYYAMDYWGQGTSVTVSS. SEQ ID NO: 12: ENVLTQSPAIMSASPGEKVTMTCRASSNVISSYVHWYQQRSGASPKLWIYSTSNLASGVPARFSGSGSGTSYSLTISSVEAEDAATYYCQQYSGYPLTFGAGTKLEL.
[0012] Preferably, said hinge region comprises the CD8α hinge region.
[0013] Preferably, said transmembrane domain comprises the CD8α transmembrane domain and / or the CD28 transmembrane domain, preferably the CD8α transmembrane domain.
[0014] Preferably, the signaling domain comprises CD3ζ.
[0015] Preferably, the signaling domain further comprises any one or a combination of at least two of 4-1BB, CD28 intracellular domain, DAP10, or OX40.
[0016] Preferably, the CLL1-targeting chimeric antigen receptor further comprises a signal peptide.
[0017] Preferably, the signal peptide comprises the CD8α signal peptide and / or the IgGκ light chain signal peptide.
[0018] In a preferred technical solution, the CLL1-targeting chimeric antigen receptor comprises a signal peptide, an anti-CLL1 antibody, a CD8α hinge region, a CD8α transmembrane region, 4-1BB, and CD3ζ.
[0019] In some specific embodiments, the CLL1-targeting chimeric antigen receptor is 19C1-CAR and comprises the amino acid sequence set forth in SEQ ID NO: 13, wherein: SEQ ID NO: 13: MALPVTALLLPLALLLHAARPQIVLTQSPAIMSASPGEKVTMTCSASSSVSYMYWYQQKPGSSPRLLIFDTSNLASGVPVRFSGSGSGTSYSLTISRMEAEDAATYYCQQWSSYPLTFGAGTKLELKGGGGSGGGGSGGGGSQVQLQQSGAELMKPGAS VKISKATGYTFSSYWIEWVKQRPGHGLEWIGEIFPGSGSIKYNEKFKGKATFTADTSSNTAYMQLSSLTSEDSAVHYCARGGTYNDYSLFDYWGQGTTLTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLL LSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR*.
[0020] In some specific embodiments, the CLL1-targeting chimeric antigen receptor is 23D7-CAR and comprises the amino acid sequence set forth in SEQ ID NO: 14, wherein: SEQ ID NO: 14: MALPVTALLLPLALLLHAARPQIVLTQSPAIMSASPGEKVTMTCSASSSVSYIYWYQQKPGSSPGLLIYDTSNLASGVPVRFSGSGSGTSYSLTISRMEAEDAATYYCQQWSSFPPTFGAG TKLELKGGGGSGGGGSGGGSQVQLQQPGSDLVRPGASVKLSCKASGYTFTRYWMHWVKQRPGHGLEWIGYIYPGSGTSNYDEKFKSKATLTVDTSSSTAYMQLSSLTSEDSAVYYCTREA RYTMDYWGQGTSVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEE EEGGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR*.
[0021] In some specific embodiments, the CLL1-targeting chimeric antigen receptor is 27H4-CAR and comprises the amino acid sequence set forth in SEQ ID NO: 15, wherein: SEQ ID NO: 15: MALPVTALLLPLALLLHAARPDIVMSQSPSSLAVSVGEKVTMSCKSSQSLLYSDNQKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVKAEDLAVYYCQQYYTYPYT FGGGTKLEIKGGGGSGGGGSGGGGSEVQLQQSGPELVKPGASVKISKASGYSFTGYHMHWVKQSHVKSLEWIGRINPYNGAASHNQKFKDKATLTVDKSSSTAYMELHSLTSEDSAVYYCARG WDYDGGYYAMDYWGQGTSVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRF PEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR*.
[0022] In some specific embodiments, the CLL1-targeting chimeric antigen receptor is H27H4-CAR and comprises the amino acid sequence set forth in SEQ ID NO: 16, wherein: SEQ ID NO: 16: MDMRVPAQLLGLLLLWLRGARCDIQMTQSPSSLSASVGDRVTITCKSSQSLLYSDNQKNYLAWYQQKPGKAPKLLIYWA STRESGVPSRFSGGSGTDFTLTISSLQPEDFATYYCQQYYTYPYTFGQGTKLEIKGGGGSGGGGSGGGSEVQLVQSGAEVKKPGASVKVSCKASGYTFTGYH MHWVRQAPGQRLEWMGRINPYNGAASHNQKFKDRVTITRDTSASTAYMELSSLRSEDTAVYYCARGWDYDGGYYAMDYWGQGTLVTVSSTTTPAPRPPTPAPTIA SQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSAD APAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR*.
[0023] In some specific embodiments, the CLL1-targeting chimeric antigen receptor is 1075.7-CAR and comprises the amino acid sequence set forth in SEQ ID NO: 17, wherein: SEQ ID NO: 17: MALPVTALLLPLALLLHAARPENVLTQSPAIMSASPGEKVTMTCRASSNVISSYVHWYQQRSGASPKLWIYSTSNLASGVPARFSGSGSGTSYSLTISSVEAEDAATYYCQQYSGYPLTFGA GTKLELGGGGSGGGGSGGGGSDIQLQESGPGLVKPSQSLSLTCSVTGYSITSAYYWNWIRQFPGNKLEWMGYISYDGRNNYNPSLKNRISITRDTSKNQFFLKLNSVTTEDTATYYCAKEGDY DVGNYYAMDYWGQGTSVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFP EEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR*.
[0024] In embodiment 2, the present application provides a nucleic acid molecule comprising a gene encoding the CLL1-targeting chimeric antigen receptor described in embodiment 1.
[0025] In some specific embodiments, the nucleic acid molecule comprises the nucleic acid sequence shown in SEQ ID NO: 18 and is the coding gene for 19C1-CAR. SEQ ID NO: 18: atggccctcccagtcacagctctgctgctcccactcgccctgctgctgcacgccgcacggcctcagatcgtcctcacccagtctccagccatcatgagcgcctctccaggcgagaaggtgacaatgacttgttccgcaagcagctcagttagttacatgtattggtaccagcagaaaccaggctcttctccaaggctcctgatcttcgacacttctaacctggcatccggagtcccagtgcggttcagcggcagcggcagtggaacatcttatagcctgactattagccggatggaggcagaagatgcagctacctactactgtcaacagtggtctagttatccactcacttttggtgcagggaccaagctggagctcaaaggtggaggaggatctggcggcggagggagtggaggaggcggctcacaggtccaactgcagcaatctggtgcagaactgatgaagcctggagcaagcgttaaaatctcttgcaaagcaacaggatacaccttttcttcctactggatagagtgggtgaaacaaagaccaggacacggac tggaatggataggagagatctttcctggcagcggctcaatcaagtataacgagaagttcaaagggaaagccaccttcacagccgatacctcttctaatacagcctatatgcagctgtcatccctgaccagcgaagattctgctgttcactactgtgcacgcggaggaacatacaatgactactctctgtttgactattggggacagggcaccacactgactgtgagttctactacgacccctgcaccgcggccgcctactcctgcacctacaatcgcaagtcagccactgagtctcagacccgaagcatgccgccctgctgcaggcggagctgtccatacacgcggactggactttgcatgcgatatatacatctgggcaccactggccggcacttgcggcgtgctgctcctgtccctcgtgattaccctgtactgcaaacgcggcaggaagaagctcctgtatatctttaaacagcccttcatgaggccagtgcagaccactcaagaggaagacggttgtagctgccggtttcccgaggaagaagagggaggctgcgagctccgcgtgaagttctcccgctcagccgatgcacccgcctatcagcaagggcagaaccagctgtacaatgagctcaacctgggaagaagggaggaatatgacgttctggataaacggcgcggtcgcgatcccgaaatgggtgggaagcctcgcaggaagaatcctcaggaagggctctacaatgagctgcagaaagacaaaatggcagaggcctattctgaaatcggcatgaagggcgagcgccgcagaggcaaaggacacgacggcctgtaccagggcctgtctacagccaccaaggacacctatgacgctctccacatgcaagccctgccaccaaggtga。
[0026] In some specific embodiments, the nucleic acid molecule comprises the nucleic acid sequence shown in SEQ ID NO: 19 and is the coding gene for 23D7-CAR. SEQ ID NO: 19: atggctctccctgttactgcactcctgctcccactggcactgctgctgcatgccgctcggccacaaatagttctgactcagagtcctgccattatgtcagcctctcctggagagaaggtcacaatgacttgctctgcctctagtagtgtgtcttacatatactggtaccagcagaagcctggttcttctcccggactgctgatctatgacacatccaatctggcttcaggcgttcccgtcagattcagcgggtctggatctggcacaagctattctctgaccatctcaagaatggaggctgaagatgctgctacttattattgccaacagtggtcttcctttccaccaaccttcggtgcaggtaccaagctcgaactcaaaggtggaggaggaagcggaggaggcggtagtggtggaggtgggtcccaagttcagctgcaacagcccggatctgatctggttcggcccggagctagcgtgaaactgtcttgcaaggctagcggatacactttcacccgctattggatgcactgggttaagcagcggccaggacacggactggagtggattggctatatctacccaggcagcgggacaagtaactacgatgagaaattcaagagtaaggctactctgactgtcgatacaagttcctcaaccgcttacatgcagctctcttcactcaccagcgaagacagtgctgtttattactgcaccagggaagctcggtacaccatggattattggggtcaaggaacttctgtgacagtgtcaagcactacgacccctgcaccgcggccgcctactcctgcacctacaatcgcaagtcagccactgagtctcagacccgaagcatgccgccctgctgcaggcggagctgtccatacacgcggactggactttgcatgcgatatataca .
[0027] In some specific embodiments, the nucleic acid molecule comprises the nucleic acid sequence shown in SEQ ID NO: 20 and is the coding gene for 27H4-CAR. SEQ ID NO: 20: tgggtgggaagcctcgcaggaagaatcctcaggaagggctctacaatgagctgcagaaagacaaaatggcagaggcctattctgaaatcggcatgaagggcga gcgccgcagaggcaaaggacacgacggcctgtaccagggcctgtctacagccaccaaggacacctatgacgctctccacatgcaagccctgccaccaaggtga.
[0028] In some specific embodiments, the nucleic acid molecule comprises the nucleic acid sequence shown in SEQ ID NO: 21 and is the coding gene for H27H4-CAR. SEQ ID NO: 21:
[0029] In some specific embodiments, the nucleic acid molecule is SEQ ID NO: 22 It contains the nucleic acid sequence shown below and is the coding gene for 1075.7-CAR. SEQ ID NO: 22:
[0030] In a third aspect, the present application provides an expression vector comprising the nucleic acid molecule according to the second aspect.
[0031] Preferably, the expression vector is a viral or non-viral vector comprising the nucleic acid molecule of embodiment 2.
[0032] Preferably, the viral vector comprises one of a lentiviral vector, a retroviral vector, or an adeno-associated viral vector.
[0033] Preferably, the non-viral vector comprises one of the following: a Piggybac transposon system, a Sleeping Beauty transposon system, or a nanovector. .
[0034] In embodiment 4, the present application provides a recombinant lentivirus prepared in a mammalian cell transfected with the expression vector and a helper plasmid described in embodiment 3.
[0035] In embodiment 5, the present application provides a chimeric antigen receptor immune cell expressing the CLL1-targeting chimeric antigen receptor according to embodiment 1.
[0036] In the present application, immune cells expressing a CLL1-targeting chimeric antigen receptor use the antigen-binding domain of the chimeric antigen receptor to target CLL1-positive tumor cells, exerting the killing function of the immune cells to secrete the cytokine IFN-γ, thereby achieving killing effect against CLL1 tumors with different E:T (Effector cell:Target cell).
[0037] Preferably, the nucleic acid molecule according to aspect 2 is integrated into the genome of the immune cell of said chimeric antigen receptor.
[0038] Preferably, said chimeric antigen receptor immune cell comprises an expression vector according to aspect 3 and / or a recombinant lentivirus according to aspect 4.
[0039] Preferably, the immune cells include any one of T cells, NK cells, or macrophages.
[0040] Preferably, said T cells comprise αβT cells and / or γδT cells.
[0041] In an embodiment, the present application provides a pharmaceutical composition comprising an immune cell of a chimeric antigen receptor according to embodiment 5.
[0042] Preferably, the pharmaceutical composition further comprises any one or a combination of at least two of a pharma- ceutically acceptable vector, excipient, or diluent.
[0043] In embodiment 7, the present application provides the use of a CLL1-targeting chimeric antigen receptor according to embodiment 1, a nucleic acid molecule according to embodiment 2, an expression vector according to embodiment 3, a recombinant lentivirus according to embodiment 4, an immune cell of the chimeric antigen receptor according to embodiment 5, or a pharmaceutical composition according to embodiment 6 in the preparation of a medicament for treating a malignant tumor.
[0044] Preferably, the malignancy comprises acute myeloid leukemia.
[0045] In embodiment 8, the present application provides a method for treating cancer, comprising administering to a patient an effective dose of a chimeric antigen receptor immune cell of embodiment 5 or a pharmaceutical composition of embodiment 6, and simultaneously, separately, or sequentially administering one or more anti-tumor agents.
[0046] Preferably, said cancer comprises acute myeloid leukemia. Effect of the Invention
[0047] Compared with the prior art, the present application has the following beneficial effects:
[0048] (1) This application constructs a CAR molecule using an anti-CLL1 antibody as the antigen-binding domain, and T cells expressing the CLL1-targeting CAR exert killing effects on CLL1-positive tumor cells with different E:T depending on the CAR element, in which H27H4-CAR-T has the optimal killing function.
[0049] (2) After co-culture with CLL1-positive tumor cells, the present CLL1-targeting CAR-T cells secreted large amounts of the cytokine IFN-γ, demonstrating the specific killing effect of CAR-T against CLL1 tumor cells. [Brief description of the drawings]
[0050] [Figure 1] Expression status of CLL1 in different tumor cells. [Diagram 2] FIG. 1 is a schematic diagram of the structure of a CLL1-targeting chimeric antigen receptor. [Figure 3A] FIG. 3A is a graph of a lentiviral expression vector containing the H27H4 CAR gene. [Figure 3B] FIG. 3B is the location of H27H4 CAR in a lentiviral expression vector. [Figure 4] Positive rate of CAR expression in different CAR-T cells. [Diagram 5] This is the killing rate of CAR-T targeting CLL1 against Raji-CLL1 cells. [Figure 6] This shows the secretion status of IFN-γ after killing target cells by CAR-T targeting CLL1. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0051] In order to further explain the technical means and effects of the present application, the present application will be further described below with reference to examples and drawings. It can be understood that the specific embodiments described herein are merely for the purpose of interpreting the present application and do not limit the present application.
[0052] Unless otherwise specified in the examples, specific techniques or conditions are carried out according to techniques or conditions described in the literature in this field, or according to the product instructions. Unless otherwise specified, reagents or equipment used are ordinary products that can be purchased through regular channels.
[0053] Example 1. Derivation of anti-CLL1 antibodies In this embodiment, anti-CLL1 antibodies 19C1, 23D7, 27H4, humanized 27H4 (H27H4) and 1075.7 (Patent US8536310B2) were selected as antigen-binding domains to construct CAR molecules, where 19C1 comprises variable regions as shown in SEQ ID NO: 1-2, 23D7 comprises variable regions as shown in SEQ ID NO: 3-4, 27H4 comprises variable regions as shown in SEQ ID NO: 5-6, H27H4 comprises variable regions as shown in SEQ ID NO: 7-8, and 1075.7 comprises variable regions as shown in SEQ ID NO: 11-12.
[0054] Example 2 Tumor cell expression of CLL1 In this example, FITC anti-human CD371 (CLL1) antibody (biolegend) was used to incubate with target cells Jurkat and KG-1a, and then expression of CLL1 in the target cells was detected using a flow cytometer.
[0055] As a result, as shown in FIG. 1, THP-1, U937 and HL-60 were CLL1-positive cells, while Jurkat and KG-1a were CLL1-negative cells.
[0056] Example 3 Design of chimeric antigen receptors In this example, a chimeric antigen receptor targeting CLL1 was designed, and the structural diagram is shown in FIG. 2. The chimeric antigen receptor comprises a CD8α signal peptide, a single-chain antibody (Anti-CLL1 scFv) that specifically binds to the CLL1 antigen, a CD8α hinge region and a transmembrane region, a 4-1BB costimulatory domain, and a CD3ζ signaling domain. The specific CAR molecules were as follows: (1) 19C1-CAR: CD8α signal peptide, Anti-CLL1 scFv(19C1), CD8αhinge+TM, 4-1BB, and CD3ζ. (2) 23D7-CAR: CD8α signal peptide, Anti-CLL1 scFv(23D7), CD8αhinge+TM, 4-1BB, and CD3ζ. (3) 27H4-CAR: CD8α signal peptide, Anti-CLL1 scFv(27H4), CD8αhinge+TM, 4-1BB, and CD3ζ. (4) h27H4-CAR: IgGκ light chain signal peptide, Anti-CLL1 scFv(H27H4), CD8α hinge+TM, 4-1BB, and CD3ζ. (5) 1075.7-CAR: CD8α signal peptide, Anti-CLL1 scFv(1075.7), CD8αhinge+TM, 4-1BB, and CD3ζ.
[0057] wherein the amino acid sequence of the CD8α signal peptide is as set forth in SEQ ID NO:23, the nucleic acid sequence thereof is as set forth in SEQ ID NO:24, the amino acid sequence of the IgGκ light chain signal peptide is as set forth in SEQ ID NO:25, the nucleic acid sequence thereof is as set forth in SEQ ID NO:26, the amino acid sequence of the CD8α hinge is as set forth in SEQ ID NO:27, the nucleic acid sequence thereof is as set forth in SEQ ID NO:28, the amino acid sequence of the CD8α TM is as set forth in SEQ ID NO:29, the nucleic acid sequence thereof is as set forth in SEQ ID NO:30, the amino acid sequence of 4-1BB is as set forth in SEQ ID NO:31, and the nucleic acid sequence thereof is as set forth in SEQ ID NO:32. The amino acid sequence of CD3ζ is as shown in SEQ ID NO:33, and the nucleic acid sequence is as shown in SEQ ID NO:34. SEQ ID NO: 23: MALPVTALLLPLALLLHAARP. SEQ ID NO: 24: atggcactgccagtgacagccctgctgctgccactggccctgctgctgcacgcagcacgccct。 SEQ ID NO: 25: MDMRVPAQLLGLLLLWLRGARC。 SEQ ID NO: 26: atggatatgagggttcctgcacaactcctgggactcctcctgctctggctgagaggcgcaagatgt。 SEQ ID NO: 27: TTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACD。 SEQ ID NO: 28: accacgacgccagcgccgcgaccaccaacaccggcgcccaccatcgcgtcgcagcccctgtccctgcgcccagaggcgtgccggccagcggcggggggcgcagtgcacacgagggggctggacttcgcctgtgat。 SEQ ID NO: 29: IYIWAPLAGTCGVLLLSLVITLYC。 SEQ ID NO: 30: atctacatctgggcgcccttggccgggacttgtggggtccttctcctgtcactggttatcaccctttactgc。 SEQ ID NO: 31: KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL。 SEQ ID NO: 32: aagagaggcaggaagaagctgctgtacatcttcaagcag cccttcatgcgccccgtgcagacaacccaggaggaggacggctgcagctgtcggttcccagaggaggaggagggaggatgtgagctg。 SEQ ID NO: 33: RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR. SEQ ID NO: 34: agggtgaagttttctcggagcgccgatgcaccagcatatcagcagggacagaatcagctgtacaacgagctgaatctgggcaggcgcgaggagtacgacgtgctggataagcggagaggcagagatcccgagatgggaggcaagccaaggaggaagaaccctcaggag ggcctgtataatgagctgcagaaggacaagatggccgaggcctactctgagatcggcatgaagggagagcggagaaggggcaagggacacgatggcctgtatcagggcctgagcacagccaccaaggacacctacgatgcactgcacatgcaggccctgccacctagg.
[0058] Example 4 Construction of an expression vector for CLL1-targeting chimeric antigen receptor (1) Based on the CAR molecule designed in Example 3, the CAR-encoding gene was codon-optimized to promote efficient expression in human-derived cells, and the CAR-encoding gene was whole-gene synthesized (Guangzhou IGE Biotechnology Co., Ltd.).
[0059] (2) The full-length CAR gene and the empty vector pCDH-EF1-MCS were cleaved with two enzymes, EcoRI and BamHI, and then digested with the enzyme for 30 minutes in a water bath at 37°C. DNA electrophoresis was then performed using a 1.5% agarose gel, and the product was purified with an agarose gel to recover the reagent kit (Amane Co., Ltd.). The enzyme digestion product was then purified and recovered.
[0060] (3) Prepare the ligation system shown in Table 1, ligate the CAR gene fragment with the linearized pCDH-EF1-MCS at 22°C for 1 hour, and directly transform the ligation product into competent cells of Stbl3 E. coli. Spread 200 μL of the transformation product onto an ampicillin-resistant LB plate and incubate overnight in an incubator at 37°C upside down. The next morning, randomly select three monoclonal clones for colony PCR identification, and sequence identify the positive clones.
[0061] [Table 1]
[0062] Illustratively, the lentiviral expression vector pBG-27H4 containing the 27H4 CAR gene was constructed as shown in Figures 3A and 3B.
[0063] Example 5 Lentivirus Packaging In this example, a four-plasmid system was used to carry out lentiviral packaging for the lentiviral expression vector constructed in Example 4. The specific steps are as follows:
[0064] (1) A four-plasmid system consisting of a lentivirus expression vector, helper plasmids gag / pol, Rev, and VSV-G was mixed with PEI transfection reagent, and then added to a certain volume of serum-free DMEM, mixed uniformly, and left for 15 minutes.
[0065] (2) The above mixture was placed in a T75 cell flask containing 293T cells, gently mixed uniformly, and cultured at 37°C in a 5% CO2 cell incubator for 6 hours.
[0066] (3) After 6 h, the medium was replaced with fresh medium, culture was continued, 10 mM sodium butanoate solution was added, and after 72 h, the lentivirus culture supernatant was collected for purification and detection.
[0067] Example 6. Obtaining and amplifying T cells Thirty milliliters of whole blood was collected from each volunteer and diluted by mixing the peripheral blood with saline in a 1:1 ratio. Ficoll lymphocyte separation solution was added to a centrifuge tube, and the diluted peripheral blood was gradually added. The tube was centrifuged at 1,500 rpm for 30 minutes, and the PBMC layer was gently aspirated and transferred to another centrifuge tube.
[0068] PBMCs were washed multiple times with saline and transferred to and cultured in X-VIVO medium (containing 50 ng / mL OKT3 and 300 IU / mL IL-2). After isolating PBMCs, they were activated with X-VIVO (containing 50 ng / mL OKT3 and 300 IU / mL IL-2). After 2 days, the medium was replaced with medium containing 300 IU / mL X-VIVO for expansion. Thereafter, the cells were counted once every 2 days and replaced with fresh medium containing 300 IU / mL X-VIVO, and the cell concentration was adjusted to (0.5-1) × 10 6 The cells were maintained at 10 cells / mL and observed continuously for 10 days.
[0069] Example 7 Preparation of CAR-T cells In this example, RetroNectin was used to improve the infection efficiency of lentiviruses into T cells, and the steps were as follows.
[0070] 30 μg of RetroNectin was coated on the inside of a 6-well plate and kept in a cell incubator at 37°C for 2 hours. RetroNectin was aspirated, and the coated 6-well plate was blocked with Hank's solution containing 2.5% BSA and kept in a cell incubator at 37°C for 0.5 hours. The blocking solution was aspirated, and the 6-well plate was washed with Hank's solution containing 2% hepes. X-VIVO medium was added, and an appropriate amount of lentivirus solution was added. The plate was centrifuged at 2000g for 2 hours, the supernatant was discarded, and 1 × 10 6 T cells (CD3 positive >90%) were added, centrifuged at 1000g for 10 min, and placed in a cell incubator at 37°C with 5% CO2 and constant humidity to culture, and the above steps were repeated the next day.
[0071] The amount of lentivirus added was as shown in Table 2.
[0072] [Table 2]
[0073] A flow cytometer was used to detect the expression of CAR molecules on the surface of T cells. CAR expression was detected using CLL1-Fc fusion protein (Acrobiosystems). The secondary antibody was FITC-Labeled anti-human Fc. T cells not transfected with CAR (T mock) were used as a negative control.
[0074] As shown in Figure 4 and Table 3, the results showed that the CAR expression positive rate of 19C1-CAR-T cells was 13.28%, the CAR expression positive rate of 23D7-CAR-T cells was 37.49%, the CAR expression positive rate of 27H4-CAR-T cells was 39.44%, the CAR expression positive rate of H27H4-CAR-T cells was 33.59%, and the CAR expression positive rate of 1075.7-CAR-T cells was 5.09%.
[0075] [Table 3]
[0076] Example 8 Killing function of CAR-T cells In this embodiment, the xCELLigence real-time label-free dynamic analysis technology (RTCA) was used to perform automated detection of cell killing effects throughout the entire process. The xCELLigence® real-time markerless cell analyzer (RTCA) is based on microelectronic impedance technology, and a large number of metal microelectrodes are built into the bottom of the E-plate plate. When adherent cells adhere to the metal microelectrodes, the cell number, diameter, and adhesion ability all affect the current conduction between the metal microelectrodes, causing changes in the impedance value, which are extremely minute and sensitive, and the toxic effect of cells directly or indirectly affects the impedance value. Therefore, xCELLigence can monitor the cytotoxic effect of molecular targets.
[0077] The steps were as follows:
[0078] (1) Dilute anti-CD40 in a fixed volume of 1× Tether Buffer and apply 50 μL of the diluted anti-CD40 to each well of an E-Plate View 96-well plate. The coating solution was made by adding 40, and the mixture was incubated at room temperature in the dark for 3 hours. Three holes were made in each group.
[0079] (2) Discard the coating solution, gently wash the wells twice with 200 μL of PBS, add 50 μL of 1640 medium containing 2% FBS to each well, place the E-Plate View 96-well plate into the xCELLigence instrument (the instrument had been placed in the incubator 1 h prior), and balance at 37°C for 1 h. The background value was then measured.
[0080] (3) Stable Raji cells overexpressing CLL1 (Raji-CLL1) were adopted as target cells, target cell suspension was prepared and cell density was measured, 50,000 cells / 50 μL were added to each well, and the final volume of each well was 100 μL. The plate was incubated at room temperature for 30 min, and the E-Plate View 96-well plate was placed back into the instrument again, and the software was operated to collect data, and the impedance was detected once every 5 min, and the detection time was 2 h.
[0081] (4) Effector cell suspensions (i.e., CAR-T cells) and negative control cell suspensions (i.e., non-transfected T cells) of different E:T were prepared, respectively, and 50 μL of diluted effector cell suspension or negative control cell suspension was added to each well, 50 μL of medium was added to the blank group, and 50 μL of 1× Cytolysis Solution was added to the positive control group, and incubated at room temperature for 30 min to ensure that the effector cells were evenly distributed on the fixed target cells.
[0082] (5) The E-Plate View 96-well plate was placed into the instrument again, and the software was operated to collect data. The impedance was detected once every 5 min, and the detection time was 16 h. After the experiment was completed, the data was stored and analyzed.
[0083] The results are shown in Figure 5. After 16h incubation with Raji-CLL1 at different E:T (1:1, 2:1, 4:1), 19C1-CAR-T, 23D7-CAR-T, 27H4-CAR-T, H27H4-CAR-T, or 1075.7-CAR-T could all effectively kill Raji-CLL1 cells, and the larger the E:T, the stronger the killing ability. Here, H27H4-CAR-T had the strongest killing ability, the killing ability of 27H4-CAR-T was similar to H27H4-CAR-T, followed by 23D7-CAR-T, and the killing ability of 19C1-CAR-T and 1075.7-CAR-T was weak, and T mock, which was not transfected with CAR, could not kill Raji-CLL1, which means that the killing activity of anti-CLL1 CAR-T depends on the CAR element.
[0084] Example 9. CAR-T cell response to IFN-γ after co-culture with tumor cells In this example, a Human IFN-γ ELISA reagent kit (Neobioscience) was used to detect the concentration of IFN-γ cytokine released by CAR-T cells, and the amount of IFN-γ secreted by CAR-T after co-culture with target cells was analyzed. Specifically, CLL1-positive cells Raji-CLL1, HL60, and U937 were used as positive target cells, and CLL1-negative cells Raji were used as negative target cells.
[0085] CAR-T cells and different target cells were incubated together at E:T = 1:1 for 16 hours, and the supernatant was taken and the amount of IFN-γ secreted in the culture supernatant was detected by enzyme-linked immunosorbent assay (ELISA). The detection principle was a two-antibody sandwich ELISA method, where an ELISA plate was coated with anti-human IFN-γ antibody, and during the experiment, human IFN-γ in the sample or standard bound to the coated antibody, and the released components were washed away. Biotinylated anti-human IFN-γ antibody and avidin labeled with horseradish peroxidase were added sequentially, and the anti-human IFN The -γ antibody binds to human IFN-γ bound to the coating antibody, and biotin specifically binds to avidin to form an immune complex, and the released components are washed away. A color-developing substrate (TMB) is added, which is catalyzed by horseradish peroxidase to produce a blue color, and after adding the end solution, it turns yellow. The OD value is measured at a wavelength of 450 nm using a plate reader, and the IFN-γ concentration is proportional to OD450. The concentration of IFN-γ in the sample is calculated by drawing a calibration curve.
[0086] The results, as shown in Figure 6, showed that 19C1-CAR-T, 23D7-CAR-T, 27H4-CAR-T, H27H4-CAR-T, or 1075.7-CAR-T released large amounts of IFN-γ after co-culture with Raji-CLL1, HL60, or U937, but did not release large amounts of IFN-γ after co-culture with Raji cells, implying that the killing of CAR-T cells targeting CLL1 has specificity.
[0087] In summary, the CLL1-targeting CAR-T cells of the present application have significant killing effect on CLL1-positive tumor cells in different E:T, and secrete large amounts of the cytokine IFN-γ after co-culture with tumor cells, which has the prospect of application in the treatment of CLL1-positive tumors.
[0088] The present application describes the detailed method of the present application through the above examples, but the applicant declares that the present application is not limited to the above detailed method, that is, it does not mean that the present application must be carried out depending on the above detailed method. Those skilled in the art should understand that any improvements to the present application, equivalent replacement of each raw material of the product of the present application, addition of auxiliary ingredients, selection of specific forms, etc. are all within the protection scope and disclosure scope of the present application.
Claims
1. comprising an antigen-binding domain, a hinge region, a transmembrane domain, and a signal transduction domain; the antigen-binding domain is an anti-CLL1 antibody; 1. A CLL1-targeting chimeric antigen receptor, comprising: The antigen-binding domain comprises the amino acid sequence shown in SEQ ID NO: 3 and SEQ ID NO: 4, or The antigen-binding domain comprises the amino acid sequence shown in SEQ ID NO: 5 and SEQ ID NO: 6, or The antigen-binding domain comprises an amino acid sequence represented by SEQ ID NO: 7 and an amino acid sequence represented by SEQ ID NO: 8; The CLL1-targeted chimeric antigen receptor.
2. The hinge region comprises a CD8α hinge region. The CLL1-targeted chimeric antigen receptor of claim 1.
3. The transmembrane domain comprises a CD8α transmembrane domain and / or a CD28 transmembrane domain; The CLL1-targeted chimeric antigen receptor of claim 1 or 2.
4. The signaling domain comprises CD3ζ. A CLL1-targeted chimeric antigen receptor according to any one of claims 1 to 3.
5. The signaling domain further comprises any one or a combination of at least two of 4-1BB, CD28 intracellular domain, DAP10, or OX40. The CLL1-targeted chimeric antigen receptor of claim 4.
6. The CLL1-targeted chimeric antigen receptor further comprises a signal peptide. A CLL1-targeted chimeric antigen receptor according to any one of claims 1 to 5.
7. The signal peptide comprises a CD8α signal peptide and / or an IgGκ light chain signal peptide. The CLL1-targeted chimeric antigen receptor of claim 6.
8. The CLL1-targeting chimeric antigen receptor comprises a signal peptide, an anti-CLL1 antibody, a CD8α hinge region, a CD8α transmembrane domain, 4-1BB, and a CD3ζ. A CLL1-targeted chimeric antigen receptor according to any one of claims 1 to 7.
9. The CLL1-targeting chimeric antigen receptor comprises the amino acid sequence set forth in SEQ ID NO: 14; or The CLL1-targeting chimeric antigen receptor comprises the amino acid sequence shown in SEQ ID NO: 15; or The CLL1-targeting chimeric antigen receptor comprises the amino acid sequence shown in SEQ ID NO:
16. A CLL1-targeted chimeric antigen receptor according to any one of claims 1 to 8.
10. A nucleic acid molecule comprising a gene encoding a CLL1-targeted chimeric antigen receptor according to any one of claims 1 to 9.
11. The nucleic acid molecule comprises the nucleic acid sequence set forth in SEQ ID NO: 19, or The nucleic acid molecule comprises the nucleic acid sequence shown in SEQ ID NO: 20, or The nucleic acid molecule comprises the nucleic acid sequence shown in SEQ ID NO:
21. The nucleic acid molecule of claim 10.
12. An expression vector comprising the nucleic acid molecule of claim 10 or 11.
13. The expression vector is a viral or non-viral vector comprising the nucleic acid molecule of claim 10 or 11, The viral vector includes any one of a lentiviral vector, a retroviral vector, and an adeno-associated viral vector; The non-viral vector includes any one of a Piggybac transposon system, a Sleeping Beauty transposon system, or a nanovector; The expression vector of claim 12.
14. The expression vector of claim 12 or 13 and a helper plasmid are prepared in a transfected mammalian cell. A recombinant lentivirus comprising a nucleic acid molecule according to claim 10 or 11.
15. A method for the production of a chimeric antigen receptor (CLL1) comprising: Chimeric antigen receptor immune cells.
16. The chimeric antigen receptor comprising a nucleic acid molecule according to claim 10 or 11 incorporated into the genome of an immune cell. An immune cell of the chimeric antigen receptor described in claim 15.
17. The chimeric antigen receptor immune cell comprises an expression vector according to claim 12 or 13 and / or a recombinant lentivirus according to claim 14. An immune cell of a chimeric antigen receptor according to claim 15 or 16.
18. The immune cells include any one of T cells, NK cells, or macrophages. An immune cell of a chimeric antigen receptor according to any one of claims 15 to 17.
19. The T cells include αβT cells and / or γδT cells.
19. An immune cell of the chimeric antigen receptor described in claim 18.
20. 20. The chimeric antigen receptor of claim 15, comprising an immune cell. Pharmaceutical compositions.
21. The composition further comprises one or a combination of at least two of a pharma- ceutically acceptable vector, excipient, or diluent.
21. The pharmaceutical composition of claim 20.
22. Use of a CLL1-targeting chimeric antigen receptor according to any one of claims 1 to 9, a nucleic acid molecule according to claim 10 or 11, an expression vector according to claim 12 or 13, a recombinant lentivirus according to claim 14, an immune cell of a chimeric antigen receptor according to any one of claims 15 to 19, or a pharmaceutical composition according to claim 20 or 21 in the preparation of a medicament for treating malignant tumors.
23. The malignant tumor comprises acute myeloid leukemia.
23. The use according to claim 22.
Citation Information
Patent Citations
Anti-cll1-specific single-chain chimeric antigen receptor (sccar) for cancer immunotherapy
JP2018504459A
